Long-term effect of low-density lipoprotein apheresis on plasma lipoproteins and coronary heart disease in native vessels and coronary bypass in severe heterozygous familial hypercholesterolemia

Metabolism: Clinical and Experimental

Volumn 47, Issue 7, 1998, Pages 863-868

  Richter, Werner O ^a,b   Donner, Markus G ^a   Höfling, Berthold ^a   Schwandt, Peter ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Institute for Lipid Metabolism and Hemorheology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; SIMVASTATIN;

ADULT; ANGINA PECTORIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HEART INFARCTION; HETEROZYGOSITY; HUMAN; LIPOPROTEIN BLOOD LEVEL; MALE; PLASMAPHERESIS; PRIORITY JOURNAL; SUDDEN DEATH; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0031863995     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(98)90127-5     Document Type: Article

References (21)

1. Stone NJ, Levy RI, Fredrickson DS, et al: Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia. Circulation 49:476-488, 1974
2. Allen JM, Thompson GR, Myant NB, et al: Cardiovascular complications of homozygous hypercholesterolemia. Br Heart J 44:361-368, 1980
3. Sprecher DL, Schaefer EJ, Kent KM, et al: Cardiovascular features of homozygous familial hypercholesterolemia: Analysis of 16 patients. Am J Cardiol 54:20-30, 1984
4. Blankenhorn DH, Nessim SA, Johnson RL, et al: Beneficial effects of combined colestipol-niacin therapy on coronary atherosclero-sis and coronary venous bypass grafts. JAMA 257:3233-3240, 1987
5. Brown G, Albers JJ, Fisher LD, et al: Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 323:1289-1298, 1990
6. Watts GB, Lewis B, Brunt JNH, et al: Effects on coronary artery disease of lipid lowering diet, or diet plus cholestyramine, in the St. Thomas' Atherosclerosis Regression Study (STARS). Lancet 339:563-569, 1992
7. Scandinavian Simvastatin Survival Study Group: Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383-1389, 1994
8. MAAS Investigators: Effect of simvastatin on coronary atheroma: The Multicentre Anti-Atheroma Study (MAAS). Lancet 344:633-638, 1994
9. Richter WO, Jacob BG, Ritter MM, et al: Three-year treatment of familial heterozygous hypercholesterolemia by extracorporeal LDL-immunoadsorption with polyclonal apolipoprotein B antibodies. Metabolism 42:888-894, 1993
10. Stoffel W, Greve V, Borberg H: Application of specific extracorporeal removal of low density lipoprotein in familial hypercholesterolemia. Lancet 2:1005-1007, 1981
11. Eisenhauer T, Armstrong VW, Wieland H, et al: Selective removal of low density lipoproteins (LDL) by precipitation at low pH: First clinical application of the HELP system. Klin Wochenschr 65:161-168, 1987
12. Seidel D, Armstrong VW, Schuff-Werner P, et al: The HELP-LDL-Apheresis Multicenter Study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. I. Evaluation of safety and cholesterol-lowering effects during the first 12 months. Eur J Clin Invest 21:375-383, 1991
13. Homma Y, Mikami Y, Tamachi H, et al: Comparison of selectivity of LDL removal by double filtration or dextran-sulfate cellulose column plasmapheresis. Atherosclerosis 60:23-27, 1986
14. Mabuchi H, Michishita I, Takeda M, et al: A new low density lipoprotein apheresis system using two dextran sulfate cellulose columns in an automated column regenerating unit (LDL-continuous apheresis). Atherosclerosis 68:19-25, 1987
15. Jacob BG, Richter WO, Schwandt P: Therapy of severe familial heterozygous hypercholesterolemia by low-density lipoprotein apheresis withimmunoadsorption: Effects of the addition of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors to therapy. Clin Invest 71:908-912, 1993
16. Schuff-Werner P, Gohlke H, Bartmann U, et al: The HELP-LDL-Apheresis Multicenter Study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. II. Final evaluation of the effect of regular treatment on LDL-cholesterol plasma concentrations and the course of coronary heart disease. Eur J Clin Invest 24:724-732, 1994
17. Tatami R, Inoue N, Itho H, et al: Regression of coronary atherosclerosis by combined LDL-apheresis and lipid-lowering drug therapy in patients with familial hypercholesterolemia: A multicenter study. Atherosclerosis 95:1-13, 1992
18. Thompson GR, Maher VM, Matthews S, et al: Familial Hypercholesterolaemia Regression Study: A randomized trial of low-density-lipoprotein apheresis. Lancet 345:811-816, 1995
19. Kroon AA, Aengevearen WRM, van der Werf T, et al: The LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation 93:1826-1835, 1996
20. Borberg H, Oette K: Experience with and conclusions from three different trials on low density lipoprotein apheresis, in Agishi T, Kawamura A, Mineshima M (eds): Therapeutic Plasmapheresis, vol 12. Utrecht, The Netherlands, VSP, 1993, pp 25-28
21. Treasure CB, Klein JL, Weintraub WS, et al: Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary heart disease. N Engl J Med 332:481-487, 1995